This follow-up study to the IMPROVE-IT trial looked primarily at elderly patients with acute coronary syndromes who were treated with a statin combination (simvastatin plus ezetimibe) or simvastatin alone. The researchers focused on patients in the older age groups, and particularly those of 75 years or more. Patients of 75 years of age or more saw the most significant improvement relative to younger age groups, according to the results. “The combination of ezetimibe and statin lead to an absolute risk reduction of 9% for the primary endpoint (the overall risk reduction was 2% absolute in the trial as a whole),” Christopher Cannon, MD, of Harvard Medical School, told DocWire News. “Of note, this group (75 years of age or more) started the trial with an average age of 79 and were followed for average of six years (until age 85) and they saw all this benefit! This tells me that we need to treat our elderly patients, as they benefit greatly.”